文献速递其他结缔组织病

巴瑞替尼治疗幼年特发性关节炎的血清生物标志物关联:JUVE-BASIS 3期试验事后分析

Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial.
PubMed 文献 · Lancet Rheumatol · 2025-09-04

该研究为JUVE-BASIS 3期试验的事后分析,纳入84例接受开放标签巴瑞替尼治疗12周的幼年特发性关节炎患者,采用Olink Explore 3072 panel检测基线与第12周血清样本。结果显示,巨噬细胞活化相关标志物(CCL7、CCL18、IL-6)及基质组成调节标志物(基质金属蛋白酶-3)的变化与临床应答正相关,应答者和超级应答者中变化幅度更大。作者认为该研究首次在巴瑞替尼干预试验中检测JIA患者血清蛋白标志物。

要点

  • 84例JIA患者中,非应答者10例(12%)、应答者27例(32%)、超级应答者47例(56%)。
  • 巨噬细胞活化标志物(CCL7、CCL18、IL-6)和基质金属蛋白酶-3的变化与临床应答正相关。
  • 应答者和超级应答者中生物标志物变化幅度高于所有患者整体水平。

核心结论

  • 巴瑞替尼治疗12周后,与巨噬细胞活化和基质组成调节相关的血清生物标志物变化与JIA临床应答正相关。
  • 作者认为,与临床应答相关的生物标志物变化可能帮助医生识别最可能对巴瑞替尼治疗有应答的患者。

研究设计与样本

  • JUVE-BASIS为随机、双盲、安慰剂对照、撤药、疗效与安全性3期试验,在20个国家75个中心开展。
  • 纳入年龄2至<18岁、符合国际风湿病学联盟分类标准的多关节型JIA(类风湿因子阳性或阴性)、扩展型少关节型JIA、附着点炎相关关节炎或幼年银屑病关节炎患者,且对一种或以上传统合成或生物改善病情抗风湿药(DMARDs)应答不足(≥12周)或不耐受。
  • 本事后分析纳入JUVE-BASIS开放标签导入期接受巴瑞替尼治疗12周的患者血清样本,采用Olink Explore 3072 panel在基线和第12周检测。
  • 2018年12月17日至2021年3月3日期间,220例患者入组JUVE-BASIS并接受至少一剂巴瑞替尼;本事后分析检测了来自84例患者的168份血清样本。
  • 84例患者中,女性67例(80%)、男性17例(20%)、白人67例(80%),平均年龄14岁(SD 2)。

主要发现

  • 基于临床应答,84例中非应答者(JIA-ACR <30%)10例(12%)、应答者(JIA-ACR 30-70%)27例(32%)、超级应答者(JIA-ACR 70-100%)47例(56%)。
  • 巴瑞替尼治疗12周后,所有患者中多个血清生物标志物出现显著变化,应答者和超级应答者中变化幅度更大。
  • 巨噬细胞活化相关标志物(CCL7、CCL18和IL-6)及基质组成调节标志物(基质金属蛋白酶-3)的变化与临床应答正相关。

关键数值与推荐

  • JIA-ACR应答分层:<30%为非应答者,30-70%为应答者,70-100%为超级应答者。
  • 采用Pearson相关分析第12周较基线的血清生物标志物变化与临床疾病活动度(JADAS-27评分)变化的相关性。
  • 巴瑞替尼介导的血清蛋白标志物药效学变化以第12周较基线的变化表示,采用重复测量混合模型得出。

临床怎么用

  • 作者认为,与临床应答相关的生物标志物变化可能使医生有可能识别最可能对巴瑞替尼治疗有应答的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Baricitinib has previously been shown to improve clinical response in patients with juvenile idiopathic arthritis (JIA) in the JUVE-BASIS trial. In this post-hoc analysis we aimed to identify whether pharmacodynamic changes in serum biomarkers in response to baricitinib treatment could help reaffirm the clinical utility of baricitinib in patients with JIA. METHODS: JUVE-BASIS was a randomised, double-blind, placebo-controlled, withdrawal, efficacy, safety, phase 3 trial, done in 75 centres in 20 countries. Eligible patients were children and adolescents (aged 2 to <18 years), with polyarticular JIA (positive or negative for rheumatoid factor), extended oligoarticular JIA, enthesitis-related arthritis, or juvenile psoriatic arthritis, as per the International League of Associations for Rheumatology criteria and an inadequate response (≥12 weeks) or intolerance to one or more conventional synthetic or biological disease-modifying antirheumatic drugs (DMARDs). Here we report post-hoc analyses of serum samples from patients who received open-label baricitinib in the 12-week lead-in period of the JUVE-BASIS trial. Samples were assessed using an Olink Explore 3072 panel at baseline and week 12. Baricitinib-mediated pharmacodynamic changes in serum protein markers were measured as changes from baseline to week 12 derived from a mixed model with repeated measurement. Pearson correlations of the change in serum biomarkers and clinical disease activity (JADAS-27 scores) comparing baseline with week 12 were examined. Proportional changes in biomarkers were classified into three response subsets based on JIA-ACR response rates: JIA-ACR <30% (non-responders), JIA-ACR 30-70% (responders), and JIA-ACR 70-100% (super-responders). People with lived experience of JIA were not involved in the design or conduct of this study. The JUVE-BASIS trial was registered with ClinicalTrials.gov, NCT03773978, and is completed. FINDINGS: Between Dec 17, 2018 and March 3, 2021, 220 patients were enrolled in JUVE-BASIS and received at least one dose of baricitinib in the open-label lead-in period. In this post-hoc analysis, 168 serum samples from 84 patients were analysed: 67 (80%) of 84 patients were female, 17 (20%) were male, 67 (80%) were White and the mean age was 14 years (SD 2). 10 (12%) of 84 were non-responders, 27 (32%) were responders, and 47 (56%) were super-responders based on clinical response. Several serum biomarkers showed significant changes following 12 weeks of baricitinib treatment for all patients with higher magnitude changes seen in responders and super-responders. Changes in biomarkers associated with macrophage activation (CCL7, CCL18, and IL-6) and regulation of matrix composition (matrix metalloproteinase-3) were positively correlated with clinical response. INTERPRETATION: To our knowledge, this is the first study measuring serum protein markers in the context of an intervention trial with baricitinib in patients with JIA. Associated biomarker changes with clinical response might allow physicians to potentially identify patients who are most likely to be responsive to baricitinib treatment. FUNDING: Eli Lilly and Company under licence from Incyte.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Krishnan V, Keller SY, Chew C, et al. Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial. Lancet Rheumatol. 2025. PMID: 40915298. doi:10.1016/S2665-9913(25)00153-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。